Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Sinopharm Tech Holdings

DB:YB2P
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
YB2P
DB
HK$1B
Market Cap
  1. Home
  2. DE
  3. Consumer Services
Company description

Sinopharm Tech Holdings Limited, an investment holding company, engages in lottery business in the People’s Republic of China and Hong Kong. The last earnings update was 52 days ago. More info.


Add to Portfolio Compare Print
  • Sinopharm Tech Holdings has significant price volatility in the past 3 months.
YB2P Share Price and Events
7 Day Returns
0%
DB:YB2P
-6.8%
DE Hospitality
-0.6%
DE Market
1 Year Returns
43.3%
DB:YB2P
-48.1%
DE Hospitality
-20.9%
DE Market
YB2P Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sinopharm Tech Holdings (YB2P) 0% 0% -4.4% 43.3% -70.1% -82.1%
DE Hospitality -6.8% -31.3% -57.6% -48.1% -63.2% -70.6%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • YB2P outperformed the Hospitality industry which returned -48.1% over the past year.
  • YB2P outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
YB2P
Industry
5yr Volatility vs Market

Value

 Is Sinopharm Tech Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sinopharm Tech Holdings. This is due to cash flow or dividend data being unavailable. The share price is €0.0215.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sinopharm Tech Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sinopharm Tech Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:YB2P PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in HKD HK$-0.01
SEHK:8156 Share Price ** SEHK (2020-01-08) in HKD HK$0.24
Germany Hospitality Industry PE Ratio Median Figure of 9 Publicly-Listed Hospitality Companies 21.1x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sinopharm Tech Holdings.

DB:YB2P PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:8156 Share Price ÷ EPS (both in HKD)

= 0.24 ÷ -0.01

-20.91x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sinopharm Tech Holdings is loss making, we can't compare its value to the DE Hospitality industry average.
  • Sinopharm Tech Holdings is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Sinopharm Tech Holdings's expected growth come at a high price?
Raw Data
DB:YB2P PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -20.91x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Hospitality Industry PEG Ratio Median Figure of 63 Publicly-Listed Hospitality Companies 0.96x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sinopharm Tech Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sinopharm Tech Holdings's assets?
Raw Data
DB:YB2P PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in HKD HK$0.01
SEHK:8156 Share Price * SEHK (2020-01-08) in HKD HK$0.24
Germany Hospitality Industry PB Ratio Median Figure of 12 Publicly-Listed Hospitality Companies 1.73x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:YB2P PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:8156 Share Price ÷ Book Value per Share (both in HKD)

= 0.24 ÷ 0.01

41.95x

* Primary Listing of Sinopharm Tech Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sinopharm Tech Holdings is overvalued based on assets compared to the DE Hospitality industry average.
X
Value checks
We assess Sinopharm Tech Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Hospitality industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Hospitality industry average (and greater than 0)? (1 check)
  5. Sinopharm Tech Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sinopharm Tech Holdings expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sinopharm Tech Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
28.9%
Expected Hospitality industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sinopharm Tech Holdings expected to grow at an attractive rate?
  • Unable to compare Sinopharm Tech Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Sinopharm Tech Holdings's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Sinopharm Tech Holdings's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:YB2P Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Hospitality Industry Earnings Growth Rate Market Cap Weighted Average 28.9%
Germany Hospitality Industry Revenue Growth Rate Market Cap Weighted Average 4%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:YB2P Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in HKD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:YB2P Future Estimates Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:YB2P Past Financials Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income *
2019-12-31 119 -45
2019-09-30 89 -38
2019-06-30 44 -34 -47
2019-03-31 28 -42
2018-12-31 25 -23 -49
2018-09-30 24 -58
2018-06-30 25 -30 -61
2018-03-31 22 -156
2017-12-31 24 -55 -164
2017-09-30 25 -172
2017-06-30 26 -59 -175
2017-03-31 32 -223

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Sinopharm Tech Holdings is high growth as no earnings estimate data is available.
  • Unable to determine if Sinopharm Tech Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:YB2P Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Sinopharm Tech Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:YB2P Future Estimates Data
Date (Data in HKD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:YB2P Past Financials Data
Date (Data in HKD Millions) EPS *
2019-12-31 -0.01
2019-09-30 -0.01
2019-06-30 -0.01
2019-03-31 -0.01
2018-12-31 -0.01
2018-09-30 -0.02
2018-06-30 -0.02
2018-03-31 -0.05
2017-12-31 -0.05
2017-09-30 -0.05
2017-06-30 -0.05
2017-03-31 -0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sinopharm Tech Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of YB2P’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Sinopharm Tech Holdings's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Consumer Services companies here
  3. Sinopharm Tech Holdings's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Sinopharm Tech Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sinopharm Tech Holdings has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sinopharm Tech Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sinopharm Tech Holdings's growth in the last year to its industry (Hospitality).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sinopharm Tech Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sinopharm Tech Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sinopharm Tech Holdings's 1-year growth to the DE Hospitality industry average as it is not currently profitable.
Earnings and Revenue History
Sinopharm Tech Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sinopharm Tech Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:YB2P Past Revenue, Cash Flow and Net Income Data
Date (Data in HKD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 118.51 -45.13 67.31
2019-09-30 88.61 -38.14 56.26
2019-06-30 43.50 -46.80 57.73
2019-03-31 28.26 -41.88 75.20
2018-12-31 24.86 -49.03 75.68
2018-09-30 24.10 -58.15 85.39
2018-06-30 25.35 -61.03 90.35
2018-03-31 21.72 -156.42 107.55
2017-12-31 23.89 -164.44 118.91
2017-09-30 24.86 -171.56 129.89
2017-06-30 26.36 -175.03 134.35
2017-03-31 32.45 -223.47 169.33
2016-12-31 28.83 -222.43 165.30
2016-09-30 25.54 -218.27 160.38
2016-06-30 34.66 -206.78 158.97
2016-03-31 26.86 -62.88 101.06
2015-12-31 77.66 -21.80 98.57
2015-09-30 121.15 7.98 98.41
2015-06-30 123.74 19.11 94.53
2015-03-31 135.23 36.63 84.76
2014-12-31 130.66 36.23 79.42
2014-09-30 103.49 25.22 72.55
2014-06-30 95.79 14.89 68.44
2014-03-31 89.51 -10.70 69.76
2013-12-31 52.35 -20.24 66.85
2013-09-30 42.06 -35.81 69.01
2013-06-30 39.10 -41.62 70.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sinopharm Tech Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sinopharm Tech Holdings has efficiently used its assets last year compared to the DE Hospitality industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sinopharm Tech Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sinopharm Tech Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Hospitality industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sinopharm Tech Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sinopharm Tech Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sinopharm Tech Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sinopharm Tech Holdings's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Sinopharm Tech Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sinopharm Tech Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sinopharm Tech Holdings Company Filings, last reported 3 months ago.

DB:YB2P Past Debt and Equity Data
Date (Data in HKD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 22.38 149.06 6.71
2019-09-30 37.24 137.14 6.65
2019-06-30 37.24 136.99 6.65
2019-03-31 -78.51 141.63 4.76
2018-12-31 -78.51 141.40 4.76
2018-09-30 -60.00 129.54 4.72
2018-06-30 -60.00 129.19 4.72
2018-03-31
2017-12-31 -22.20 117.88 9.77
2017-09-30 10.59 104.91 14.30
2017-06-30 10.59 104.38 14.30
2017-03-31
2016-12-31 104.53 97.20 13.91
2016-09-30 149.48 84.17 33.00
2016-06-30 149.48 84.17 33.00
2016-03-31
2015-12-31 324.44 79.24 71.15
2015-09-30 357.95 73.28 92.94
2015-06-30 357.95 73.28 92.94
2015-03-31
2014-12-31 354.12 68.67 124.75
2014-09-30 337.49 65.40 151.85
2014-06-30 337.49 65.40 151.85
2014-03-31
2013-12-31 41.14 133.64 7.29
2013-09-30 44.89 136.14 3.64
2013-06-30 44.89 136.14 3.64
  • Sinopharm Tech Holdings's level of debt (666.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (19.4% vs 666.1% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Sinopharm Tech Holdings's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Sinopharm Tech Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sinopharm Tech Holdings has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sinopharm Tech Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sinopharm Tech Holdings dividends.
If you bought €2,000 of Sinopharm Tech Holdings shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sinopharm Tech Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sinopharm Tech Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:YB2P Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Hospitality Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 11.3%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:YB2P Future Dividends Estimate Data
Date (Data in HK$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sinopharm Tech Holdings has not reported any payouts.
  • Unable to verify if Sinopharm Tech Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sinopharm Tech Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sinopharm Tech Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sinopharm Tech Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sinopharm Tech Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sinopharm Tech Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sinopharm Tech Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ting Chan
COMPENSATION HK$3,258,000
AGE 49
CEO Bio

Mr. Ting Chan serves as Executive Director at Sinopharm Tech Holdings Limited since October 22, 2019. He serves as the Chief Executive Officer and Compliance Officer at China Vanguard You Champion Holdings Limited (formerly B & B Group Holdings Ltd., B & B Natural Products Ltd., Bee & Bee Natural Life Products Ltd.) and served as its Head of Marketing & Business Development. Mr. Chan is responsible for the marketing and business development of the China Vanguard Group. Mr. Chan has solid experience in establishing and managing companies in the PRC. He served as Executive Chairman of Aptus Holdings Ltd. He has been Deputy Chairman at China Vanguard You Champion Holdings Limited since November 6, 2012. He has been Executive Director of Aptus Holdings Ltd., since August 27, 2004. Mr. Chan served as the Chief Executive Officer of Aptus Holdings Ltd., a subsidiary of China Vanguard Group Limited. until September 24, 2010. Mr. Chan serves as an Executive Director of China Vanguard You Champion Holdings Limited. He was awarded a degree in Economics from Macquarie University in Australia in 1993.

CEO Compensation
  • Ting's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Ting's remuneration is about average for companies of similar size in Germany.
Management Team

Kwai Lan Cheung

TITLE
Co-Founder & Executive Chairperson
COMPENSATION
HK$6M
AGE
81

Ting Chan

TITLE
Deputy Chairperson
COMPENSATION
HK$3M
AGE
49

Tung Mei Chan

TITLE
Co-Founder & Non-Executive Director
COMPENSATION
HK$660K
AGE
83

Kam Kin Ho

TITLE
Group CFO & Company Secretary
AGE
41
TENURE
3.6 yrs

Angel Kwok

TITLE
Director of Group Human Resources & Administration
AGE
43

Daniel Fung

TITLE
Director of Group Corporate Strategy & Investor Relations
AGE
49

Siu Sarah Chan

TITLE
General Counsel
COMPENSATION
HK$158K
AGE
54
TENURE
11.9 yrs
Board of Directors Tenure

Average tenure and age of the Sinopharm Tech Holdings board of directors in years:

1.5
Average Tenure
57
Average Age
  • The average tenure for the Sinopharm Tech Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Kwai Lan Cheung

TITLE
Co-Founder & Executive Chairperson
COMPENSATION
HK$6M
AGE
81

Ting Chan

TITLE
Deputy Chairperson
COMPENSATION
HK$3M
AGE
49
TENURE
7.4 yrs

Tung Mei Chan

TITLE
Co-Founder & Non-Executive Director
COMPENSATION
HK$660K
AGE
83
TENURE
7.4 yrs

Lawrence Lau

TITLE
Independent Non-Executive Director
AGE
48
TENURE
0.3 yrs

Ta-Pei Liu

TITLE
Independent Non-Executive Director
COMPENSATION
HK$240K
AGE
67
TENURE
2.3 yrs

Yanjie Cheng

TITLE
Non-Executive Director
AGE
55
TENURE
0.8 yrs

Fred Chau

TITLE
Independent Non Executive Director
AGE
57
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Oct 19 Sell Best Frontier Investments Limited Company 30. Sep 19 30. Sep 19 -42,645,000 €0.03 €-1,237,002
08. Aug 19 Buy Tak Cheung Yam Individual 08. Aug 19 08. Aug 19 1,100,000 €0.03 €35,167
02. Aug 19 Buy Siu Hoi Tse Individual 19. Jul 19 19. Jul 19 2,000,000 €0.04 €82,204
24. May 19 Buy Tak Cheung Yam Individual 22. May 19 22. May 19 5,000,000 €0.02 €109,205
20. May 19 Buy China National Pharmaceutical Group Corporation Company 10. May 19 10. May 19 650,000,000 €0.02 €15,763,941
X
Management checks
We assess Sinopharm Tech Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sinopharm Tech Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Sinopharm Tech Holdings Limited, an investment holding company, engages in lottery business in the People’s Republic of China and Hong Kong. It operates through Provision of Lottery-Related Services, Provision of Internet Plus Services, and Other Services segments. The company offers lottery-related hardware and software systems. It also provides Internet plus solution services to government affair, public security, health care, leasing, and lottery industries; and corporate management, and food and catering services. Sinopharm Tech Holdings Limited has a strategic cooperation agreement with Zhuhai Huafa Group Co. Ltd. to procure emergency medical supplies in view of the coronavirus disease (COVID-19) pandemic. The company was formerly known as China Vanguard You Champion Holdings Limited and changed its name to Sinopharm Tech Holdings Limited in June 2019. Sinopharm Tech Holdings Limited was founded in 1999 and is headquartered in Tai Po, Hong Kong.

Details
Name: Sinopharm Tech Holdings Limited
YB2P
Exchange: DB
Founded: 1999
HK$119,861,710
4,108,855,068
Website: http://www.sinopharmtech.com.hk
Address: Sinopharm Tech Holdings Limited
Wireless Centre,
Units 307-313, 3rd Floor,
Tai Po,
New Territories, Hong Kong
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 8156 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 12. Nov 2002
DB YB2P Ordinary Shares Deutsche Boerse AG DE EUR 12. Nov 2002
Number of employees
Current staff
Staff numbers
59
Sinopharm Tech Holdings employees.
Industry
Casinos and Gaming
Consumer Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 23:20
End of day share price update: 2020/01/08 00:00
Last estimates confirmation: 2019/09/27
Last earnings filing: 2020/02/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.